Claimbc69c5215b42b13c6ef856e2a68b6f816458fe2d74d954df3a9e975b665c5e48·My Arguments

Claim

A 2025 systematic review and meta-analysis of randomized controlled trials found GLP-1RA use was not associated with significant changes in risk for thyroid, pancreatic, breast, or kidney cancer, with consistent results across subgroups.

Evidence (1)

GLP-1 receptor agonists show little effect on obesity-related cancer risk
Meta-analysis of RCTs showed no significant association between GLP-1RA therapy and thyroid, pancreatic, breast, or kidney cancer risk.
https://www.2minutemedicine.com/glp-1-receptor-agonists-show-little-effect-on-obesity-related-cancer-risk/

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/bc69c5215b42b13c6ef856e2a68b6f816458fe2d74d954df3a9e975b665c5e48"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberationJoin & respond